A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Dobry ogólny stan zdrowia (zdolność do codziennych aktywności)
- •Glejak, który powrócił po wcześniejszym leczeniu (promieniowaniem i/lub chemioterapią)
- •Diagnoza potwierdzona badaniem - glejak typu IDH-wildtype, najwyższego stopnia zaawansowania
- •Widoczne zmiany w badaniu MRI mózgu
- •MRI mózgu wykonane nie więcej niż 14 dni przed rozpoczęciem badania
- •Prawidłowa funkcja nerek, wątroby i układu krwiotwórczego potwierdzona badaniami krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
The University of Texas M. D. Anderson Cancer Center
Houston, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Trial contact
Evguenia Gachimova, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.